Results 61 to 70 of about 413,339 (385)

Escape from TGF‐β‐induced senescence promotes aggressive hallmarks in epithelial hepatocellular carcinoma cells

Molecular Oncology, EarlyView.
Chronic TGF‐β exposure drives epithelial HCC cells from a senescent state to a TGF‐β resistant mesenchymal phenotype. This transition is characterized by the loss of Smad3‐mediated signaling, escape from senescence, enhanced invasiveness and metastatic potential, and upregulation of key resistance modulators such as MARK1 and GRM8, ultimately promoting
Minenur Kalyoncu, Dilara Demirci, Sude Eris, Bengisu Dayanc, Ece Cakiroglu, Merve Basol, Merve Uysal, Gulcin Cakan‐Akdogan, Fang Liu, Mehmet Ozturk, Gökhan Karakülah, Serif Senturk   +11 more
wiley   +1 more source

Repeated Remote Ischemic Conditioning Reduces Doxorubicin-Induced Cardiotoxicity

JACC. CardioOncology, 2020
Objectives: This study investigated the cardioprotective effect of repeated remote ischemic preconditioning (rRIC) on doxorubicin-induced cardiotoxicity in mice.
Quan He, PhD, Fangfei Wang, MD, Thomas D. Ryan, PhD, MD, Meghana Chalasani, BS, Andrew N. Redington, MD   +4 more
doaj  

A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro

International Journal of Nanomedicine, 2019
Purpose The primary goal of the present study was to develop the nano-drug consisting of doxorubicin and exosome derived from mesenchymal stem cells, and to explore its effect on osteosarcoma in vitro.
Hongxiang Wei, Jinyuan Chen, Sheng-lin Wang, Feihuan Fu, Xia Zhu, Chao-yang Wu, Zhoujie Liu, Guangxian Zhong, Jianhua Lin   +8 more
semanticscholar   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

The role of the microvascular network structure on diffusion and consumption of anticancer drugs [PDF]

, 2017
We investigate the impact of microvascular geometry on the transport of drugs in solid tumors, focusing on the diffusion and consumption phenomena. We embrace recent advances in the asymptotic homogenization literature starting from a double Darcy—double
Mascheroni, Pietro, Penta, Raimondo
core   +1 more source

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

Cancer, 2020
The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype‐specific prospective controlled data lacking, this study retrospectively evaluated doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone as ...
L. D’Ambrosio, Nathan Touati, J. Blay, G. Grignani, R. Flippot, A. Czarnecka, S. Piperno-Neumann, J. Martín-Broto, R. Sanfilippo, D. Katz, F. Duffaud, B. Vincenzi, D. Stark, F. Mazzeo, Armin Tuchscherer, C. Chevreau, J. Sherriff, A. Estival, S. Litière, W. Sents, I. Ray-Coquard, F. Tolomeo, A. Le Cesne, P. Rutkowski, S. Stacchiotti, B. Kasper, H. Gelderblom, A. Gronchi   +27 more
semanticscholar   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Comparative Effect of Maitake Pro4x with Chemotherapy Breast Cancer Treatment [PDF]

, 2017
Conventional treatments for breast cancer involve surgery followed by radiation and hormonal therapy and/or chemotherapy. Some of these treatments have toxic side effects.
Aguilera Braico, Diego Máximo, Balogh, Gabriela Andrea, Brie, Belen, Roldán Deamicis, Agustina   +3 more
core   +1 more source

Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins

BMC Cancer, 2018
Cancer cell resistance to therapeutics can result from acquired or de novo-mediated factors. Here, we have utilised advanced breast cancer cell culture models to elucidate de novo doxorubicin resistance mechanisms.
C. Lovitt, T. Shelper, V. Avery
semanticscholar   +1 more source

Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma

JAMA Oncology, 2020
This nonrandomized clinical trial evaluates the use of doxorubicin and pembrolizumab in patients with metastatic/unresectable anthracycline-naive sarcoma.
S. Pollack, M. Redman, K. Baker, M. Wagner, B. Schroeder, E. Loggers, Kathryn Trieselmann, Vanessa C. Copeland, Shihong Zhang, G. Black, Sabrina McDonnell, J. Gregory, Rylee Johnson, Roxanne Moore, Robin L. Jones, L. Cranmer   +15 more
semanticscholar   +1 more source